terazosin has been researched along with Cancer of Prostate in 23 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 9.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 5.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "A total of 34 men with benign prostatic hyperplasia (BPH) who have been on terazosin treatment (for the obstructive symptoms) were pathologically diagnosed with prostate cancer following surgery." | 3.71 | Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. ( Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N, 2001) |
| "The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992) |
| "The adrenergic alpha-1 and -2 adrenoceptors in human hypertrophied and non-hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity]. ( Morita, T, 1991) |
| "Patients with prostate cancer are initially treated with surgical resection, radiation or antiandrogen therapy." | 2.42 | The role of alpha-blockers in the management of prostate cancer. ( Kyprianou, N; Rowland, RG; Tahmatzopoulos, A, 2004) |
| "Treatment with prazosin (30 μM) altered the expression of several cell stress-related proteins: elevating phospho-p38α and reducing S6 kinase in both cell lines." | 1.43 | Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines. ( Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C, 2016) |
| "Terazosin or genistein treatment inhibited the growth of DU-145 cells in a dose-dependent manner, whereas had no effect on normal prostate epithelial cells." | 1.35 | Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. ( Chang, KL; Cheng, HL; Chih, TT; Hsieh, BS; Hu, YC; Huang, LW; Shyu, HW; Su, SJ, 2009) |
| "All newly diagnosed prostate cancer cases unexposed to alpha1-adrenoreceptor antagonists in the total male Veterans Affairs population during this period were also identified from the Kentucky Cancer Registry database." | 1.34 | Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. ( Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM, 2007) |
| "Androgen independent PC-3 prostate cancer cells and PC-3 transfectant clones over expressing the apoptosis suppressor bcl-2 were used as an in vitro model." | 1.32 | Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. ( Keledjian, K; Kyprianou, N, 2003) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Our results indicate that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth." | 1.31 | Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. ( Benning, CM; Kyprianou, N, 2000) |
| "Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland." | 1.31 | Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forbes, A | 2 |
| Anoopkumar-Dukie, S | 2 |
| Chess-Williams, R | 2 |
| McDermott, C | 1 |
| Batty, M | 1 |
| Pugh, R | 1 |
| Rathinam, I | 1 |
| Simmonds, J | 1 |
| Walker, E | 1 |
| McDermott, CM | 1 |
| Spencer, B | 1 |
| Christie, D | 1 |
| Chang, KL | 1 |
| Cheng, HL | 1 |
| Huang, LW | 1 |
| Hsieh, BS | 1 |
| Hu, YC | 1 |
| Chih, TT | 1 |
| Shyu, HW | 1 |
| Su, SJ | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Pan, SL | 1 |
| Guh, JH | 1 |
| Huang, YW | 1 |
| Chern, JW | 1 |
| Chou, JY | 1 |
| Teng, CM | 1 |
| Keledjian, K | 2 |
| Kyprianou, N | 8 |
| Xu, K | 1 |
| Wang, X | 1 |
| Ling, M | 1 |
| Wong, Y | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 1 |
| Tahmatzopoulos, A | 2 |
| Rowland, RG | 2 |
| Liu, SJ | 1 |
| Xu, KX | 1 |
| Wang, XF | 1 |
| Hou, SK | 1 |
| Wang, YC | 1 |
| Harris, AM | 1 |
| Warner, BW | 1 |
| Wilson, JM | 1 |
| Becker, A | 1 |
| Conner, W | 1 |
| Lane, M | 1 |
| Kimbler, K | 1 |
| Durbin, EB | 1 |
| Baron, AT | 1 |
| Konen, JC | 1 |
| Lowe, FC | 1 |
| Zelefsky, MJ | 1 |
| Ginor, RX | 1 |
| Fuks, Z | 1 |
| Leibel, SA | 1 |
| Benning, CM | 3 |
| Chon, J | 1 |
| Borkowski, A | 1 |
| Kim, G | 1 |
| Isaacs, JT | 1 |
| Jacobs, SC | 1 |
| Morita, T | 2 |
| Kondo, S | 1 |
| Alver, JE | 1 |
| Mooppan, UM | 1 |
| Kester, RR | 1 |
| Gintautas, J | 1 |
| Abadir, AR | 1 |
| Kim, H | 1 |
3 reviews available for terazosin and Cancer of Prostate
| Article | Year |
|---|---|
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; | 2016 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoi | 2004 |
2 trials available for terazosin and Cancer of Prostate
| Article | Year |
|---|---|
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind M | 1994 |
18 other studies available for terazosin and Cancer of Prostate
| Article | Year |
|---|---|
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Ce | 2016 |
Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell | 2009 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Neovascul | 2003 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell | 2003 |
Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Division; Cell Line; Humans; Male; Prazosi | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
[The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Do | 2004 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti | 2007 |
Men's health issues.
Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic | 1993 |
Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Huma | 1999 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis | 2000 |
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Endothelial Growth | 2001 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Rela | 2002 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla | 1992 |
[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Muscle Contraction; Muscle, Smooth; Norep | 1991 |
The effects of the alpha 1-adrenergic antagonists terazosin and phentolamine on prostatic adenoma and urethra in vitro.
Topics: Adenoma; Adrenergic alpha-Antagonists; Humans; In Vitro Techniques; Male; Muscle Contraction; Phento | 1989 |